Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 18/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786060 | 0.98 | AVPR1B (0.48) | AVPR1BCYP3A4GPR6 | |
| SCHEMBL15911698 | 0.95 | AVPR1B (0.46) | AVPR1BCYP3A4CCR6GPR6 | |
| SCHEMBL1786044 | 0.95 | AVPR1B (0.47) | AVPR1BCYP3A4CCR6GPR6 | |
| SCHEMBL1784581 | 0.94 | AVPR1B (0.48) | AVPR1BCYP3A4CCR6GPR6 | |
| SCHEMBL1786116 | 0.94 | AVPR1B (0.43) | AVPR1BCYP3A4GPR6 | |
| SCHEMBL1786413 | 0.94 | AVPR1B (0.49) | AVPR1BCYP3A4CCR6GPR6 | |
| Trifluoroacetic Acid SCHEMBL1785772 | 0.94 | AVPR1B (0.45) | AVPR1BCYP3A4GPR6 | |
| SCHEMBL17261273 | 0.94 | AVPR1B (0.46) | AVPR1BCYP3A4 | |
| SCHEMBL17261007 | 0.94 | AVPR1B (0.46) | AVPR1BCYP3A4 | |
| SCHEMBL16053611 | 0.94 | AVPR1B (0.46) | AVPR1BCYP3A4CCR6GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815868-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | claimed |
| EP-2114923-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2014-08-06 | — | — | EP | claimed |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2015-12-10 | — | — | US | disclosed |
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8815868-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2114923-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20120322809-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AbbVie Deutschland GmbH & Co. KG (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20110124658-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| EP-2114923-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008080973-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885CCR6 3253/4885 |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885CCR6 3253/4885 |
| US-20120322809-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885CCR6 3253/4885 |
| US-20110124658-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885CCR6 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.